Compare · BNTX vs WWB
BNTX vs WWB
Side-by-side comparison of BioNTech SE (BNTX) and Windward Bio Group AG (WWB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and WWB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $20.92B, about 15.5x WWB ($1.35B).
- WWB has been more active in the news (14 items in the past 4 weeks vs 9 for BNTX).
- BNTX has more recent analyst coverage (25 ratings vs 0 for WWB).
- Company
- BioNTech SE
- Windward Bio Group AG
- Price
- -
- -
- Market cap
- $20.92B
- $1.35B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2026
- News (4w)
- 9
- 14
- Recent ratings
- 25
- 0
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Windward Bio Group AG
Windward Bio Group is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease, or COPD, and atopic dermatitis. Our product candidates, WIN378 and WIN027, target clinically validated disease pathways and are engineered to remain in the body for extended periods of time, enabling less frequent dosing than currently available treatments. This design feature is combined with additional properties including enhanced target affinity, dual target binding or effector function silencing. We believe our product candidates have the potential to deliver better clinical outcomes while offering the convenience of less frequent dosing than currently available treatments.
Latest BNTX
- SEC Form 6-K filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
- BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
- A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
- SEC Form 6-K filed by BioNTech SE
- SEC Form 6-K filed by BioNTech SE
- BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
- BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
- SEC Form 6-K filed by BioNTech SE
Latest WWB
- Director David P Bonita bought $20,000,007 worth of shares (1,176,471 units at $17.00), converted options into 5,172,944 shares, exercised 216,668 shares at a strike of $0.02 and covered exercise/tax liability with 232 shares (SEC Form 4)
- Director Orbimed Advisors Llc bought $20,000,007 worth of shares (1,176,471 units at $17.00), converted options into 5,172,944 shares, exercised 216,668 shares at a strike of $0.02 and covered exercise/tax liability with 232 shares (SEC Form 4)
- Director Otello Stampacchia bought $29,750,000 worth of shares (1,750,000 units at $17.00) and converted options into 3,588,520 shares (SEC Form 4)
- Windward Bio to Participate at the Jefferies London Global Healthcare Conference
- Director Mufti Iqbal Rasool was granted 22,675 share options (SEC Form 4)
- Chief Operating Officer Harris Kevin Andrew was granted 33,206 shares, increasing direct ownership by 4% to 960,966 units (SEC Form 4)
- Chief Executive Officer Santarelli Luca was granted 815,755 employee share options (SEC Form 4)
- Chief Financial Officer D'Augusta Claudia was granted 180,160 employee share options (SEC Form 4)
- Director Bonita David P was granted 22,675 stock options (SEC Form 4)
- Director Stampacchia Otello was granted 22,675 share options (SEC Form 4)